REGENXBIO alternatives
10 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About REGENXBIO and its alternatives
Users searching for REGENXBIO alternatives are typically evaluating other clinical-stage gene therapy developers with AAV or viral vector platforms, late-stage retinal or neuromuscular programs, and in-house manufacturing. REGENXBIO stands out for its NAV library of over 100 AAV capsids and a focused pipeline that includes ABBV-RGX-314 for wet AMD, RGX-202 for Duchenne, and RGX-121 for Hunter syndrome. Competing companies may offer different capsid technologies, broader rare-disease portfolios, or approved products, but often lack REGENXBIO’s specific combination of in-house GMP capacity and late-stage retinal programs. Decision-makers compare vector potency, safety data, manufacturing scale, and partnership structures when assessing these options against REGENXBIO’s approach to one-time treatments.
Explore the alternatives
- N
1.Nephrogen
Healthcare & MedicalCurative gene therapies for kidney diseases
2.Beam Therapeutics
Healthcare & MedicalPrecision base editing for genetic medicines
3.Bluebird Bio
Healthcare & MedicalOne-time gene therapies for sickle cell, beta-thalassemia and CALD
4.CRISPR Therapeutics
Healthcare & MedicalPioneering CRISPR gene-edited medicines for serious diseases
- E
5.Editas Medicine
Healthcare & Medical 
6.Intellia Therapeutics
Healthcare & MedicalRevolutionize the course of medicine with CRISPR genome editing
7.Sarepta Therapeutics
Healthcare & MedicalPrecision genetic medicines for rare neuromuscular and CNS diseases
8.Spark Therapeutics
Healthcare & MedicalBreakthrough science. One moment, one day, one person at a time.
- V
9.Vertex Pharmaceuticals
Healthcare & MedicalVertex Pharmaceuticals company site
10.Voyager Therapeutics
Healthcare & MedicalLeveraging genetics to treat neurological diseases.
See more comparisons in Healthcare & Medical alternatives.
Questions about REGENXBIO alternatives
What companies offer AAV gene therapy platforms similar to REGENXBIO’s NAV technology?
Several clinical-stage developers use engineered AAV capsids for retinal and neuromuscular indications. Key differences appear in capsid diversity, manufacturing scale, and stage of clinical programs compared with REGENXBIO’s 100-plus vector library and in-house production.
How does REGENXBIO’s pipeline compare to other Duchenne gene therapy candidates?
REGENXBIO’s RGX-202 targets Duchenne with a specific microdystrophin construct and AAV vector. Other developers use different promoters, capsids, or dosing strategies, leading to variations in durability and safety profiles that require direct clinical data review.
Are there gene therapy companies with approved products that compete with REGENXBIO’s retinal programs?
A few companies have commercial AAV products for ocular or neuromuscular diseases. REGENXBIO remains clinical-stage with ABBV-RGX-314, so comparisons center on trial endpoints, vector design, and future commercial readiness versus existing approved therapies.
Which firms provide in-house manufacturing for AAV vectors like REGENXBIO?
Limited developers operate their own commercial-scale AAV facilities. REGENXBIO highlights in-house capabilities for its late-stage programs, while others rely on CDMOs, affecting timelines, cost, and supply control.
What differentiates REGENXBIO’s MPS II program from other Hunter syndrome treatments?
RGX-121 uses AAV delivery for CNS and systemic expression. Alternative approaches include enzyme replacement or different gene therapy vectors, creating distinctions in administration frequency and potential durability that patients and clinicians evaluate.